WO30070

Research code: WO30070
Research name: Randomised, multicentre, placebo-controlled phase III research evaluating the effect of Atezolizumab (ANTY-PD-L1 antibody) in monotherapy and in combination with platinum compound-based chemotherapy in previously untreated patients with locally advanced or metastatic urothelial carcinoma.
Indication: bladder
Principal researcher: Ewa Chmielowska, MD, PhD